Qyuns Therapeutics (02509) Announces Share Repurchase Update

Bulletin Express01-26

Qyuns Therapeutics (02509) disclosed a share repurchase on 26 January 2026. The company repurchased 89,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.32 to HKD 21.96, amounting to an aggregate consideration of HKD 1,952,769.28. These repurchased shares are designated as treasury shares, bringing the total number of treasury shares to 2,056,200.

Following the transaction, the total number of issued shares remained at 227,071,600. The shares outstanding (excluding treasury shares) now stand at 225,015,400, compared with the opening balance of 225,105,000 as of 21 January 2026.

Under the existing share repurchase mandate approved on 20 June 2025, the company is authorized to repurchase up to 22,207,160 shares. Including this latest transaction, the cumulative repurchases represent approximately 0.9259% of the total issued shares (excluding treasury shares) at the time of that resolution. The company is subject to a moratorium period until 25 February 2026 regarding any new share issuance or sales of treasury shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157241096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157241096","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics (02509) Announces Share Repurchase Update","media":"Bulletin Express","content":"<p>Qyuns Therapeutics (02509) disclosed a share repurchase on 26 January 2026. The company repurchased 89,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.32 to HKD 21.96, amounting to an aggregate consideration of HKD 1,952,769.28. These repurchased shares are designated as treasury shares, bringing the total number of treasury shares to 2,056,200.</p>\n<p>Following the transaction, the total number of issued shares remained at 227,071,600. The shares outstanding (excluding treasury shares) now stand at 225,015,400, compared with the opening balance of 225,105,000 as of 21 January 2026.</p>\n<p>Under the existing share repurchase mandate approved on 20 June 2025, the company is authorized to repurchase up to 22,207,160 shares. Including this latest transaction, the cumulative repurchases represent approximately 0.9259% of the total issued shares (excluding treasury shares) at the time of that resolution. The company is subject to a moratorium period until 25 February 2026 regarding any new share issuance or sales of treasury shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics (02509) Announces Share Repurchase Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics (02509) Announces Share Repurchase Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-26 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics (02509) disclosed a share repurchase on 26 January 2026. The company repurchased 89,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.32 to HKD 21.96, amounting to an aggregate consideration of HKD 1,952,769.28. These repurchased shares are designated as treasury shares, bringing the total number of treasury shares to 2,056,200.</p>\n<p>Following the transaction, the total number of issued shares remained at 227,071,600. The shares outstanding (excluding treasury shares) now stand at 225,015,400, compared with the opening balance of 225,105,000 as of 21 January 2026.</p>\n<p>Under the existing share repurchase mandate approved on 20 June 2025, the company is authorized to repurchase up to 22,207,160 shares. Including this latest transaction, the cumulative repurchases represent approximately 0.9259% of the total issued shares (excluding treasury shares) at the time of that resolution. The company is subject to a moratorium period until 25 February 2026 regarding any new share issuance or sales of treasury shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1157241096","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157241096","pubTimestamp":1769432639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics (02509) disclosed a share repurchase on 26 January 2026. The company repurchased 89,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.32 to HKD 21.96,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics(02509)公布股份回购更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics (02509) disclosed a share repurchase on 26 January 2026. The company repurchased 89,600 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 21.32 to HKD 21.96, amounting to an aggregate consideration of HKD 1,952,769.28. These repurchased shares are designated as treasury shares, bringing the total number of treasury shares to 2,056,200.\nFollowing the transaction, the total number of issued shares remained at 227,071,600. The shares outstanding (excluding treasury shares) now stand at 225,015,400, compared with the opening balance of 225,105,000 as of 21 January 2026.\nUnder the existing share repurchase mandate approved on 20 June 2025, the company is authorized to repurchase up to 22,207,160 shares. Including this latest transaction, the cumulative repurchases represent approximately 0.9259% of the total issued shares (excluding treasury shares) at the time of that resolution. The company is subject to a moratorium period until 25 February 2026 regarding any new share issuance or sales of treasury shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157241096","isCrawlerRequest":true}